Published in BMC Musculoskelet Disord on November 18, 2008
Targeting subchondral bone for treating osteoarthritis: what is the evidence? Best Pract Res Clin Rheumatol (2010) 1.33
Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? Rheumatol Int (2009) 1.25
Biochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation. BMC Musculoskelet Disord (2010) 0.95
Racial differences in biochemical knee cartilage composition between African-American and Caucasian-American women with 3 T MR-based T2 relaxation time measurements--data from the Osteoarthritis Initiative. Osteoarthritis Cartilage (2015) 0.82
Levels of Circulating MMCN-151, a Degradation Product of Mimecan, Reflect Pathological Extracellular Matrix Remodeling in Apolipoprotein E Knockout Mice. Biomark Insights (2011) 0.81
Cartilage Protective and Chondrogenic Capacity of WIN-34B, a New Herbal Agent, in the Collagenase-Induced Osteoarthritis Rabbit Model and in Progenitor Cells from Subchondral Bone. Evid Based Complement Alternat Med (2013) 0.77
Impact of treatments for osteoporosis on cartilage biomarkers in humans. Osteoporos Int (2012) 0.76
Stable sulforaphane protects against gait anomalies and modifies bone microarchitecture in the spontaneous STR/Ort model of osteoarthritis. Bone (2017) 0.75
The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum (1995) 3.93
Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol (2006) 3.80
Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann Rheum Dis (1993) 2.78
The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum (2004) 2.22
The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum (2004) 2.22
The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum (2007) 2.22
A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum (2004) 1.87
Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum (2004) 1.74
Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum (2006) 1.71
Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause (2004) 1.66
Functional estrogen receptors in adult articular cartilage: estrogen replacement therapy increases chondrocyte synthesis of proteoglycans and insulin-like growth factor binding protein 2. Arthritis Rheum (2000) 1.63
Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab (1996) 1.61
Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage (2008) 1.50
Osteoarthritis severity is sex dependent in a surgical mouse model. Osteoarthritis Cartilage (2007) 1.45
Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum (2005) 1.45
Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res Ther (2004) 1.42
Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis (2003) 1.40
Expression of genes for estrogen receptors alpha and beta in human articular chondrocytes. Osteoarthritis Cartilage (1999) 1.35
The effects of estrogen on osteoarthritis. Curr Opin Rheumatol (1998) 1.34
Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol (2006) 1.33
Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum (2008) 1.31
Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage (2006) 1.19
Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthritis Cartilage (2006) 1.19
Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study. Osteoarthritis Cartilage (2006) 1.18
In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev Technol (2005) 1.14
Estrogens, cartilage, and osteoarthritis. Joint Bone Spine (2003) 1.13
Abnormal cancellous bone collagen metabolism in osteoarthritis. J Clin Invest (1998) 1.11
Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum (2002) 1.10
Effect of hormone therapy on risk of hip and knee joint replacement in the Women's Health Initiative. Arthritis Rheum (2006) 1.09
Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum (2006) 1.08
Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. Rheumatology (Oxford) (2003) 1.08
The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res (2004) 1.06
Receptor profiling and endocrine interactions of tibolone. Steroids (2003) 1.06
Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab (1999) 1.05
Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage (2008) 1.05
Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis (2005) 1.04
Bone, not cartilage, should be the major focus in osteoarthritis. Nat Clin Pract Rheumatol (2007) 1.04
The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid samples for estimation of articular cartilage status in experimental models of destructive joint diseases. Osteoarthritis Cartilage (2006) 1.02
Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women. Reproduccion (1983) 1.00
Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis (2002) 0.95
Effects of estrogen replacement therapy on bone turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of ovariectomized cynomolgus monkeys. J Bone Miner Res (2004) 0.95
Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. DNA Cell Biol (2006) 0.95
Do subchondral bone changes exacerbate or precede articular cartilage destruction in osteoarthritis of the elderly? Gerontology (1997) 0.94
The role of bone metabolism in osteoarthritis. Curr Rheumatol Rep (2003) 0.94
Estrogen replacement therapy and the development of osteoarthritis. Epidemiology (1996) 0.92
A primate model of human postmenopausal hot flushes. J Clin Endocrinol Metab (1984) 0.87
Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women. Bone (2006) 0.85
Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas (2005) 0.85
Org OD 14 and the endometrium. Maturitas (1991) 0.84
Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. Osteoporos Int (2003) 0.84
Immunohistochemical detection of estrogen receptor alpha in articular chondrocytes from cows, pigs and humans: in situ and in vitro results. Ann Anat (2001) 0.83
The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy. Bone (2004) 0.83
Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis. Biomarkers (2008) 0.82
Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas (1991) 0.78
Estrogen receptors in cultured rabbit articular chondrocytes: influence of age. J Steroid Biochem (1988) 0.78
Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. Maturitas (1988) 0.77
Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women. Maturitas (1984) 0.75
The diagnosis of osteoporosis. J Bone Miner Res (1994) 10.90
The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med (1997) 6.15
Bacterial genome sizes determined by DNA renaturation studies. J Gen Microbiol (1970) 5.86
Serological cross-reactions between Mycoplasma genitalium and Mycoplasma pneumoniae. J Clin Microbiol (1984) 3.15
Genome size of mycoplasmal DNA. Nature (1969) 2.86
Prediction of rapid bone loss in postmenopausal women. Lancet (1987) 2.76
Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. Br Med J (1973) 2.60
The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem (1998) 2.48
Bone-density measurement. Lancet (1992) 2.38
Letter: Anticonvulsant hypomagnesaemia. Br Med J (1974) 2.30
Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ (1991) 2.12
Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest (1980) 2.04
Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N Engl J Med (1987) 2.03
Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int (2002) 2.01
Complete DNA sequence of yeast chromosome II. EMBO J (1994) 1.97
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem (1994) 1.93
The sequence of 16S rRNA from Mycoplasma strain PG50. DNA (1985) 1.91
Circular, repetitive DNA in yeast. Biochim Biophys Acta (1972) 1.88
A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum (2004) 1.87
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med (1985) 1.81
Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet (1981) 1.81
Catalysis of DNA reassociation by the Escherichia coli DNA binding protein: A polyamine-dependent reaction. J Mol Biol (1977) 1.73
Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA (2001) 1.72
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Bone mineral content in the forearm measured by photon absorptiometry. Principles and reliability. Scand J Clin Lab Invest (1975) 1.65
Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int (2003) 1.63
Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab (1996) 1.61
Epidemiology of postmenopausal spinal and long bone fractures. A unifying approach to postmenopausal osteoporosis. Clin Orthop Relat Res (1982) 1.59
Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis? Ann Rheum Dis (1985) 1.54
Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem (1998) 1.51
The long-term impact of 2-3 years of hormone replacement therapy on cardiovascular mortality and atherosclerosis in healthy women. Climacteric (2006) 1.50
Should subchondral bone turnover be targeted when treating osteoarthritis? Osteoarthritis Cartilage (2008) 1.50
Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med (2006) 1.49
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Accuracy of measurements of body composition by dual-energy x-ray absorptiometry in vivo. Am J Clin Nutr (1993) 1.48
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int (2007) 1.47
Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15-year follow-up study. Bone (1996) 1.45
Bone Gla protein (osteocalcin) assay standardization report. J Bone Miner Res (1990) 1.45
Postmenopausal osteoporosis: therapeutic options. Climacteric (2005) 1.45
Effect of an energy-restrictive diet, with or without exercise, on lean tissue mass, resting metabolic rate, cardiovascular risk factors, and bone in overweight postmenopausal women. Am J Med (1993) 1.44
Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year period. Osteoporos Int (1991) 1.42
Circular DNA molecules controlling synthesis and transfer of the surface antigen (K88) in Escherichia coli. J Gen Microbiol (1972) 1.41
Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes (1978) 1.41
Validation of body composition by dual energy X-ray absorptiometry (DEXA). Clin Physiol (1991) 1.41
Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann Rheum Dis (2003) 1.40
Incorporation and distribution of strontium in bone. Bone (2001) 1.40
Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand (1981) 1.40
Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism (1991) 1.40
Value of biomarkers in osteoarthritis: current status and perspectives. Ann Rheum Dis (2013) 1.40
Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res (1991) 1.37
Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers (2009) 1.37
Bone mass and its relationship to age and the menopause. J Clin Endocrinol Metab (1987) 1.36
Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ (1989) 1.34
Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int (2006) 1.33
Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases. Osteoporos Int (2006) 1.33
The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J Clin Endocrinol Metab (1988) 1.33
Mechanism of circadian variation in bone resorption. Bone (2002) 1.33
Effect of puberty on rates of bone growth and mineralisation: with observations in male delayed puberty. Arch Dis Child (1979) 1.31
Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab (1991) 1.30
Efficient identification of postdischarge surgical site infections: use of automated pharmacy dispensing information, administrative data, and medical record information. J Infect Dis (1999) 1.29
Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) (1989) 1.29
Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet (1978) 1.29
Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int J Obes (1984) 1.28
Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol (Copenh) (1979) 1.28
Age- and menopause-associated variations in body composition and fat distribution in healthy women as measured by dual-energy X-ray absorptiometry. Metabolism (1995) 1.28
Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ (1992) 1.27
Prevalence of decreased bone mass in rheumatoid arthritis. Relation to anti-inflammatory treatment. Clin Rheumatol (1984) 1.27
Calcium supplementation and postmenopausal bone loss. Br Med J (Clin Res Ed) (1984) 1.27
Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care (1995) 1.26
The transplanted parathyroid gland: evaluation of cryopreservation and other environmental factors which affect its function. Surgery (1974) 1.25
Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone (2000) 1.24
Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium. Clin Endocrinol (Oxf) (1982) 1.24
Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy (2009) 1.24
Influence of menopause on serum lipids and lipoproteins. Maturitas (1990) 1.23
Bone changes occurring spontaneously and caused by estrogen in early postmenopausal women: a local or generalised phenomenon? Br Med J (Clin Res Ed) (1986) 1.22
Usefulness of regional bone measurements in patients with osteoporotic fractures of the spine and distal forearm. J Nucl Med (1987) 1.21
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int (2001) 1.20
Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. Am J Med (1990) 1.20
The effect of glucocorticoids on bone mass in rheumatoid arthritis patients. Influence of menopausal state. Arthritis Rheum (1985) 1.19
Hyponatremia and hyperkalemia in relation to hyperglycemia in insulin-treated diabetic out-patients. Clin Chim Acta (1982) 1.19
Comparison of single- and dual-photon absorptiometry in postmenopausal bone mineral loss. J Nucl Med (1985) 1.19
Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage (2006) 1.19
Long-term reproducibility of bone mineral content measurements. Scand J Clin Lab Invest (1977) 1.19
Body composition and calcium metabolism in adult treated coeliac disease. Gut (1991) 1.18
Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res (1999) 1.18
Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med (2000) 1.17
Lithium, hypercalcemia, hypermagnesemia, and hyperparathyroidism. Lancet (1976) 1.17
The mineral content in bone. Measured by means of 27.5 keV radiation from 125I. Acta Radiol Suppl (1972) 1.16